India SEBI Regulatory Enforcement Actions — March 10, 2026

Completed 100% acquisition of DPJ TOT at ₹1,342 Cr EV (Sep 30, 2025), expanding road infra footprint post 51% stake buy in Feb 2026, arm's length SPA Sep 2025

DPJ TOT revenue grew from ₹122 Cr FY23 to ₹147 Cr FY25 (17.2% YoY FY24), outperforming flat infra peers amid toll stabilization

Granted Japanese patent (No. 2022-568620) for V-ATPase inhibitors in viral treatments, strengthening IP portfolio under SEBI Reg 30 disclosure

Full ownership of DPJ TOT (inc. 2021) aligns with strategic development objectives, no pledges or insider sales noted

Patent covers methods for treating viral infections, potential revenue catalyst vs neutral biotech IP trends

Enterprise value ₹1,342 Cr for ₹147 Cr FY25 revenue implies ~9.1x EV/Revenue multiple, reasonable for toll roads vs sector avg 7-10x

Disclosure by Manoj Jain (Membership F-7998) flags positive sentiment (7/10 materiality), no insider selling in biorefinery peers

ARTL (wholly-owned) now controls DPJ TOT fully, enabling operational synergies and capex reinvestment over dividends

Enhances antiviral therapeutics moat, script GODAVARIB (544279), positive vs mixed sentiment in pharma filings

Adani's 17.2% YoY FY24 revenue beat Godavari's implied flat IP milestones, signaling infra outperformance

DPJ TOT revenue slowed to 2.8% YoY FY25 from 17.2% FY24, potential post-acquisition margin pressure in toll roads

FY25 flat performance (₹147 Cr) vs FY23-24 acceleration, watch for toll volume declines QoQ

Granted patent lacks explicit forward guidance on licensing/revenue, mixed antiviral market adoption risk

₹1,342 Cr EV for maturing asset (inc. 2021) at 9.1x FY25 revenue, premium vs peers if synergies underdeliver

Full acquisition uses cash for control vs buybacks/dividends, no YoY cap alloc trends disclosed

SEBI Reg 30 filing positive but no operational metrics (volumes/costs), potential neutral sentiment shift

Acquiree CAGR 9.7% FY23-25 lags Adani group infra averages (~15%), integration drag possible

Full DPJ TOT ownership at ₹1,342 Cr EV unlocks toll escalation upside, aligns with India road capex cycle

Japanese patent for viral inhibitors offers licensing alpha in post-pandemic therapeutics, IP portfolio growth

ARTL control of DPJ TOT (₹147 Cr FY25 rev) enables cost optimization vs FY24 17.2% growth trajectory

V-ATPase tech strengthens vs biotech peers, potential M&A valuation premium (no deals disclosed)

Acquisition timing (Mar 10, 2026) post SPA Sep 2025, capitalizes on FY25 stabilization for multi-year toll growth

Japan patent bolsters global IP, alpha in biorefinery exports amid neutral sector sentiment

9.1x EV/Rev on acquiree undervalued vs infra M&A avg 10x+, post-integration ROE upside

Adani's full buyout of road asset (17.2% YoY FY24 rev growth) signals 1/2 filings pursuing inorganic expansion, implies capex shift from dividends

Godavari's patent grant (positive sentiment) vs Adani's flat FY25 trends highlights bifurcated themes, alpha in therapeutics amid enforcement disclosures

Aggregate YoY slowdown (Adani acquiree 2.8% FY25 vs 17.2% FY24), common in infra (1/2 filings), watch margin compression

Both filings bullish (no penalties), 100% positive sentiment in enforcement stream, contrasts typical bearish regulatory actions

Adani's ₹1,342 Cr EV deal prioritizes growth over payouts, no buybacks/splits noted across filings

Monitor post-Mar 10, 2026 operational metrics for FY26 revenue rebound from 2.8% FY25 YoY

Track ARTL synergies and toll volumes QoQ, potential earnings call disclosure on capex

Watch for licensing deals or guidance on viral drug pipeline, H2 2026 catalysts

No transactions noted; monitor pledges/holdings changes post-acquisition for conviction

Track ROE/margins post-patent, compare YoY to biorefinery peers

EV sensitivity to Sep 30, 2025 base, watch for FY26 forecasts in next Reg 30 filing

Aggregate insider trading in infra/biotech, any shifts from current neutral activity